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Anti-P56/75Rabbit anti-HPV16 L2 serum (anti-P56/75) neutralizes multiple oncogenic human papillomaviruses (HPVs).
We inoculated HeLa cells with HPV16 pseudovirus (16PV) and with anti-P56/75-bound 16PV (16PV-Ab).
Both 16PV and 16PV-Ab attached equally well to the cell surface. However, the cell-attached L1 protein of
16PV became trypsin-resistant after incubation at 37 °C, whereas approximately 20% of the cell-attached
16PV-Ab L1 remained trypsin-sensitive. Confocal microscopy of HeLa cells inoculated with 16PV revealed
packaged DNA in the nucleus at 22 h after inoculation; however, nuclear DNA was not detected in cells
inoculated with 16PV-Ab. Electron microscopy of HeLa cells inoculated with 16PV showed particles located
in multivesicular bodies, lamellar bodies, and the cytosol after 4 h; no cytosolic particles were detected after
inoculation with 16PV-Ab. These data suggest that anti-P56/75 inhibits HPV infection partly by blocking viral
entry and primarily by blocking the transport of the viral genome to the nucleus.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus (HPV) consists of a double-stranded DNA
genome (8 kb) and a non-enveloped icosahedral capsid composed of
two capsid proteins, L1 (major) and L2 (minor) (Howley and Lowy,
2001). Based on nucleotide similarities among their L1 genes, HPVs
have been classiﬁed into more than 100 genotypes. HPV genotype 16
(HPV16) is the most prevalent type linked to cervical cancer
worldwide.
HPV propagates only in differentiating keratinocytes (zur Hausen,
2002), which are difﬁcult to culture on a large scale. Hence, it is
difﬁcult to prepare HPV virions for detailed studies of the HPV
infection process. As a surrogate virus, an infectious HPV pseudovirus,
comprising an HPV capsid containing a reporter plasmid, has been
developed (Buck et al., 2004). When SV40 T-antigen-positive cells are
transfected with expression plasmids for L1 and L2 together with a
reporter plasmid carrying SV40-ori, the replicating reporter plasmid is
packaged into the capsid formed by the assembly of L1 and L2 in the
nucleus, thereby producing pseudovirus (PV). Human cells inoculated
with PV express a readily detectable level of the reporter.Thus far, many studies with PVs have indicated that PV binds to
heparin sulfate proteoglycans (HSPGs) on the surface of cells
(Giroglou et al., 2001) and then enters the cells by endocytosis
mediated by clathrin, caveolin, or the tetraspaninmicrodomain region
(Bousarghin et al., 2003; Day et al., 2003; Hindmarsh and Laimins,
2007; Smith et al., 2008; Spoden et al., 2008). The vesicles containing
PV trafﬁc to endosomal compartments, including late endosomes,
lysosomes, and cavoesomes (Day et al., 2003; Smith et al., 2008). The
mechanisms of viral egress from the organelles and viral uncoating
are not clear, but it has been suggested that the minor capsid protein,
L2, plays an important role in these events (Day et al., 2004; Kämper
et al., 2006; Richards et al., 2006).
L2 is composed of about 470 amino acids. The C-terminal region of
L2 binds to L1 (Okun et al., 2001; Finnen et al., 2003). The N-terminal
region, with an amino acid sequence that is highly conserved among
various HPV types, contains several cross-neutralization epitopes
(Pastrana et al., 2005; Kondo et al., 2007). Antiserum obtained from
rabbits immunized with a synthetic peptide representing the
sequence of HPV16 amino acid residues 56 to 75 (anti-P56/75)
neutralizes genotype 16, 18, 31, and 58 PVs (Kondo et al., 2007),
as 7well as HPV16 authentic virions produced by raft culture (Conway
et al., 2009).
In the present study, we incubated HPV16 PV (16PV) with anti-
P56/75 serum or normal rabbit serum and used this to inoculate HeLa
cells. We examined the inoculated cells for 16PV attachment to the
182 Y. Ishii et al. / Virology 406 (2010) 181–188cell surface, internalization of 16PV, and the intracellular localization
of 16PV particles and DNA. The results showed that approximately
20% of the antibody-bound 16PV particles failed to enter the cell, and
the internalized antibody-bound 16PV particles failed to transport the
packaged DNA to the nucleus.
Results
Neutralization of 16PV by anti-P56/75
To examine the effect of anti-P56/75 on pseudoviral infection,
HeLa cells were inoculated with 16PV (2.5 μg) preincubated with
normal rabbit serum or 16PV (2.5 μg) preincubated with anti-P56/75
serum. After 2 days in culture, cells positive for EGFP were identiﬁed
by ﬂuorescence microscopy (Fig. 1A) and were counted by ﬂuores-
cence-activated cell sorting (FACS) (Fig. 1B). Cells inoculated with
16PV preincubated with normal rabbit serum efﬁciently expressed
EGFP (Fig. 1A, upper panel), whereas cells inoculated with 16PV
preincubated with anti-P56/75 (1:20 dilution) did not express the
reporter protein (Fig. 1A, lower panel). A FACS analysis of 10,000 cells
inoculated with 16PV preincubated with normal rabbit serum
revealed 6000 EGFP-positive cells (Fig. 1B). In contrast, cells
inoculated with 16PV preincubated with anti-P56/75 serum (1:20
dilution) showed almost no EGFP expression by FACS analysis. These
data indicate that the incubation of 16PV with anti-P56/75 serumFig. 1.Neutralization of 16PV by anti-P56/75. The pseudovirus 16PV (2.5 μg or 0.25 μg of L1, a
serum or normal rabbit serum in growthmedium (500 μl) and incubated at 37 °C for 30 min.
of the cells was observed by ﬂuorescence microscopy (A), and the number of EGFP-positive c
experiments were performed in duplicate.prevented the expression of the PV reporter protein in inoculated
cells.
Effect of anti-P56/75 on 16PV attachment to and entry into HeLa cells
To determine the effect of anti-P56/75 on the attachment of 16PV
to the cell surface, HeLa cells were incubated with 16PV preincubated
with normal rabbit serum or 16PV preincubated with anti-P56/75
serum for 1 h at 4 °C, harvested, lysed, and analyzed by Western
blotting with anti-HPV16 L1 monoclonal antibody (Fig. 2A). The
antibody recognized similar levels of the L1 virus protein in both cell
samples, indicating that the binding of anti-P56/75 to 16PV did not
block the attachment of 16PV to the cells.
To investigate the effect of anti-P56/75 on the entry of the virus
into cells, HeLa cells inoculated with 16PV preincubated with normal
rabbit serum or 16PV preincubated with anti-P56/75 serum were
incubated at 37 °C for the indicated times and harvested in the
presence or absence of trypsin. After being washed, the cells were
lysed and analyzed for the presence of L1 by Western blotting with
anti-HPV16 L1 monoclonal antibody (Fig. 2B). In cells without
incubation (time 0), L1 was not present in the lysates of cells
harvested with trypsin, indicating that L1 had been separated from
the cells and digested by trypsin (Supplementary Fig. 1A). Thus, 16PV
was still on the surface of the cells before incubation at 37 °C. After 2 h
of incubation, some L1 was not digested by trypsin during harvestings indicated), which carries an expression plasmid for EGFP, wasmixedwith anti-P56/75
HeLa cells were inoculated with themixture and incubated. After 2 days, the EGFP signal
ells among 104 cells was counted by ﬂuorescence-activated cell sorting (FACS) (B). The
Fig. 2. Attachment and entry of 16PV to HeLa cells. (A) Attachment of 16PV to cells. The 16PV (2.5 μg of L1) wasmixed with anti-P56/75 serum or normal rabbit serum (ﬁnal dilution,
1:20) in growth medium (500 μl) and incubated at 37 °C for 30 min. HeLa cells were inoculated with the mixture and incubated at 4 °C for 1 h. The cells were washed with cold PBS,
harvested in PBS containing 2.5 mM EDTA, and then lysed. L1 protein in the lysate was detected by Western blotting with mouse anti-HPV16 L1 antibody. Experiments were
performed independently in triplicate. (B) Trypsin resistance of L1. Cells were inoculated and incubated at 4 °C for 1 h as described above. The cells were washed with growth
medium and incubated in growth medium at 37 °C for 0, 2, 4, 8, and 22 h. At each time point, the cells were harvested in PBS containing 2.5 mM EDTA (trypsin−) or trypsin (trypsin
+) and then lysed. L1 protein in the lysate was detected by Western blotting with mouse anti-HPV16 L1 antibody. Arrows indicate full-sized and degraded L1. Asterisks indicate an
unknown protein that reacted with the antibody. Experiments were performed independently in triplicate.
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cells. Degraded, smaller L1 fragments appeared in cell lysates at 2 h
and became prominent at 4 h. The levels of both intact and degraded
L1 were reduced at 22 h, suggesting that L1 was further degraded. The
levels of trypsin-resistant L1 in the lysates of cells inoculated with
anti-P56/75-bound 16PV (right panel) were approximately 80% of
those in lysates of cells inoculated with 16PV in the absence of anti-
P56/75 (left panel and Table 1). Thus, approximately 20% of the cell-
attached antibody-bound PV failed to enter the cells.
The cells that internalized 16PV in the absence of anti-P56/75
showed reporter protein expression at 2, 4, and 8 h of incubation
following inoculation (Supplementary Fig. 1B), indicating that the
internalized 16PV was delivered through the infectious pathway.Effect of anti-P56/75 on the subcellular localization of 16PV L1 and
packaged DNA in HeLa cells
To examine the subcellular localizations of 16PV L1 and the DNA
packaged inside the capsid, the DNA was labeled by replacing
thymidine with 5-ethynil-2′-deoxyuridine (EdU) during replication.
EdU-labeled DNA in 16PV lost the ability to express the reporter gene
in inoculated 293FT cells (Supplementary Fig. 2). HeLa cells were
inoculated with EdU-labeled 16PV preincubated with normal rabbit
serum or preincubated with anti-P56/75 serum. The cells were then
incubated at 37 °C for the indicated times, ﬁxed with methanol, and
ﬂuorescently stained for L1 (Alexa Fluor 555, red signal) and EdU-Table 1
Percentage of trypsin-resistant L1a.
Incubation at 37 °C
2 h 4 h
16 V 64.3 (16.5) 64.9 (3.71)
16 V+anti-P56/75 52.1 (17.1) 53.9 (9.13)
Results are presented as average percentage of three independent experiments
(standard deviation).
a Cell-attached L1 at 0 h was set to 100%.labeled DNA (Alexa Fluor 488, green signal). Where L1 and the DNA
colocalized, the overlapping signals appeared as yellow dots (Fig. 3).
Confocal ﬂuorescence microscopy images show the intracellular
localization of L1 and EdU-DNA in HeLa cells inoculated with 16PV
preincubated with normal rabbit serum (Fig. 3A, left panel) and in
HeLa cells inoculated with 16PV preincubated with anti-P56/75
serum (Fig. 3A, right panel). In each panel, differential interference
contrast images are presented to the right of the ﬂuorescence images.
The numbers of red, green, and yellow dots at different incubation
times are given in Fig. 3B.
In cells inoculated with EdU-labeled PV16 preincubated with
normal rabbit serum (Fig. 3A, left panel), capsids with EdU-labeled
DNA (yellow dots) and empty capsids or capsids with unlabeled DNA
(red dots) were located along the surface of the cells, at a ratio of
about 3:2, respectively, before incubation at 37 °C (time 0 h). After
incubation at 37 °C for 2 h, some yellow and red dots appeared in the
cytoplasm, representing internalization of 16PV. Between 4 and 8 h of
incubation, the number of yellow and red dots in the cytoplasm
decreased (Fig. 3B). At 22 h, several green dots (approximately 6±3
dots/cell), indicating EdU-labeled DNA that had separated from the
capsid, appeared in the nucleus, and some small red dots, represent-
ing L1, were seen in the perinuclear region (Figs. 3A and B). Thus, the
packaged DNA was released from the capsid and entered the nucleus
during incubation at 37 °C.
In cells inoculated with EdU-labeled 16PV preincubated with anti-
P56/75 serum, many yellow and red dots were located along the cell
surface at time 0 (Fig. 3A, right panel). At 2 h, large yellow dots, which
were probably aggregates of 16PV, appeared on the cell surface,
where they remained until 22 h. At 22 h, red dots were observed in
the perinuclear region, but no green dots were ever present in the
nucleus (Figs. 3A and B).
Effect of anti-P56/75 on the subcellular localization of 16PV
particles in HeLa cells
The subcellular localization of 16PV particles in HeLa cells was
studied using transmission electron microscopy (Fig. 4). HeLa cells
were inoculated with 16PV preincubated with normal rabbit serum or
Fig. 3. Subcellular localization of L1 protein and packaged DNA. (A) The 16PV (2.5 μg of L1) containing 5-ethynil-2′-deoxyuridine (EdU)-labeled DNA was preincubated with anti-
P56/75 serum (ﬁnal dilution, 1:20) or normal rabbit serum in growth medium (500 μl) at 37 °C for 30 min and used to inoculate HeLa cells. The cells were incubated at 4 °C for 1 h,
washed with growthmedium, incubated in growthmedium at 37 °C for 0, 2, 4, 8, and 22 h, ﬁxedwith methanol, and ﬂuorescently labeled for L1 (Alexa Fluor 555, red dots) and EdU-
labeled DNA (Alexa Fluor 488, green dots). Colocalized L1 and DNA appear as yellow dots. Confocal ﬂuorescence microscopy images of cells inoculated with 16PV in the absence (left
panel) and presence of anti-PV56/75 (right panel) are presented, along with the differential interference contrast images. The small arrowheads indicate a large aggregate of
antibody-bound 16PV particles, thought to be on the cell surface. The arrows indicate an aggregate that appears to be at the contact site between two adjacent cells. Experiments
were performed twice independently. N: nucleus, C: cytoplasm. (B) Numbers of red, yellow, and green dots in the cells. Red (L1), yellow (L1 and DNA), and green (DNA) dots were
counted in 20 randomly selected cells of the indicated samples. Error bars represent the standard deviation.
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of 16PV served as a control. After a 4-h incubation, the cells were ﬁxed
and embedded. Ultra-thin sections (70 nm) were cut, stained with 4%
uranyl acetate, and viewed under a transmission electron microscope.
HeLa cells incubated with either 16PV preparation showed
particles with an approximate diameter of 55 nm on their surface
(Figs. 4B and C). The electron-dense particles were probably capsids
containing DNA, as these particles were not detected on the cells
incubated without 16PV (Figs. 4A and E). The particles of antibody-
bound 16PV formed a large aggregate (Fig. 4C), but no particle
aggregation was detected in the cells inoculated with 16PV in the
absence of antibody (Fig. 4B). This result is consistent with the
confocal microscopy images of the cells at 2 and 4 h. The aggregate
was likely unable to enter the cell and remained on the cell surface.
The particles of 16PVwere located inmultivesicular bodies (MVBs;
200–500 nm and 500–1,000 nm in diameter), which are late endo-
somes containing multiple lumenal vesicles; in lamellar bodies (LBs),which are lysosomal organelles containing multiple concentric
membrane layers (Schmitz and Müller, 1991); in lysosome-like
MVBs (L-MVBs), which are relatively electron-dense organelles; and
in the cytosol (Figs. 4D and F, capsids are indicated by arrows). There
were fewer particles of antibody-bound 16PV, and these were located
in MVBs and L-MVBs, but not in the large MVBs (500–1000 nm in
diameter) or the cytosol (Table 2). Some 16PV particles were attached
to the limiting membrane of MVBs (Fig. 4F), whereas no particles of
antibody-bound 16PV were attached to the membrane (Fig. 4G).
These observations suggest that any antibody-bound 16PV that
entered the cell did not egress from the endosomal compartments.
Discussion
In the present study, the binding of anti-P56/75 to 16PV did not
affect the attachment of 16PV to HeLa cells, as shown byWestern blot
analysis of cell lysates and by confocal ﬂuorescence microscopy. In
Fig. 4. Subcellular localization of 16PV particles. The 16PV (10 μg of L1) was mixed with anti-P56/75 serum or normal rabbit serum (ﬁnal dilution, 1:10) in growth medium (1 ml)
and incubated at 37 °C for 30 min. HeLa cells (6×105) were inoculated with the mixture, incubated at 37 °C for 4 h, ﬁxed, and embedded. Ultra-thin sections were cut and stained
with uranyl acetate for observation by transmission electron microscopy. A and E: Cells were not inoculated with 16PV. B, D, and F: Cells were inoculated with 16PV preincubated
with normal rabbit serum. C and G: Cells were inoculated with 16PV preincubated with anti-P56/75 serum. Arrows in B and C indicate particles on the cell surface. The arrowhead in
B indicates an invagination of the plasma membrane. The arrows in D indicate particles in endosomal compartments (MVBs, LBs, and L-MVBs); cytosolic particles are boxed, and an
enlargement is shown in the inset. The arrows in F indicate particles located near the limiting membranes of L-MVBs. The arrow in G indicates particles in MVBs. Experiments were
performed twice independently. LB: lamellar body; L-MVB: lysosome-like multiple vesicular body; Ly: lysosome; M: mitochondrion; MVB: multiple vesicular body; N: nucleus; PM:
plasma membrane.
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Table 2
Intracellular distribution of electron-dense particles with an approximate diameter of
55 nm at 4 h post-inoculation.
Number of 55-nm electron-dense particlesa
Cell
surface
LBs MVBs L-MVBs Cytosol
#1 #2 #1 #2 #1 #2 #1 #2 #1 #2
16PV 27 140 2.5 0.4 13 19 12 15 1.8 1.4
16PV+anti-P56/75 28 110 0 0 7 1.4 4.3 0.8 0 0
Experiments were performed twice independently.
a The number of particles is shown as the average from ﬁve cells photographed at a
magniﬁcation of ×20,000.
186 Y. Ishii et al. / Virology 406 (2010) 181–188both the presence and absence of antibody, 16PV particles were
observed on the surface of inoculated HeLa cells. Thus, anti-P56/75
did not neutralize 16PV by interfering with viral attachment to cells.
The binding of anti-P56/75 to 16PV partially blocked the entry of
cell-attached 16PV into HeLa cells. After incubation of inoculated HeLa
cells at 37 °C, the trypsin resistance of the L1 protein of antibody-
bound 16PV was only 80% of the trypsin resistance of 16PV L1 in the
absence of antibody, indicating that 20% of antibody-bound 16PV
remained on the cell surface, where it appeared to form aggregates
visible by confocal microscopy after 2 to 22 h of incubation. The
aggregates were also observed by electron microscopy, suggesting
that the aggregates that formed after the attachment of PV to the
surface were not degraded and remained for a long period on the cell
surface. This indicates that anti-P56/75 did not mediate the formation
of large aggregates of virion by acting as a bivalent tether. In a similar
previous experiment, 16PV bound with RG-1, a monoclonal antibody
recognizing amino acids 17–36 of L2, accumulated in the extracellular
matrix contacting the cell edges (Day et al., 2008).
The binding of anti-P56/75 to 16PV blocked the release of the
packaged DNA from the internalized PV to the nucleus. On confocal
ﬂuorescencemicrographs, DNA released from capsids was observed in
the nuclei of cells inoculated with 16PV preincubated with normal
serum and incubated for 22 h; however, no evidence of released DNA
was seen in cells inoculated with antibody-bound 16PV.
Electron micrographs of HeLa cells at 4 h after the inoculation
clearly showed that cells inoculated with antibody-bound 16PV
contained fewer 16PV particles than cells inoculated with 16PV in
the absence of antibody, even though the antibody impaired the
internalization efﬁciency of 16PV by only about 20%. It is possible that
the capsids of antibody-bound 16PV were easily denatured in the
cells, making some particles undetectable by electron microscopy.
Based on the electron micrographs, antibody-bound 16PV entered the
cells by endocytosis, but failed to egress from endosomal vesicles. In
the absence of antibody, 16PV particles were seen in MVBs, LBs, and
the cytosol (Fig. 4C), whereas particles of antibody-bound 16PV were
observed in some MVBs, but not in the cytosol. Previous studies have
shown that the most BPV1 virions, BPV1 PV, HPV16 capsids, and
HPV31 capsids accumulate in endosomal vesicles (Zhou et al., 1995;
Bossis et al., 2005; Bousarghin et al., 2003), and a small fraction of
inoculated HPV16 capsids or BPV1 PV has been detected in the cytosol
(Yang et al., 2003; Bossis et al., 2005). In general, particles in
endosomal vesicles are degraded after fusion of the vesicles with
lysosomes (Day et al., 2003). In the present study, the particles
observed in the cytosol might have been those that escaped
degradation.
The structure of particles in the cytosol must be altered in order to
release the viral genome from the virion. These dynamic structural
changes may be induced by cyclophilin A, a cytosolic peptidyl-prolyl
cis/trans isomerase that facilitates 16PV infection (Bienkowska-Haba
et al., 2009), and by cell cycle progression throughmitosis, which is an
important event for HPV infection (Pyeon et al., 2009).The attachment of particles to the limiting membranes of MVBs, as
reported in the present study, may be vital for particles to exit the
vesicles, considering that no antibody-bound 16PV particles were
found attached to MVB limiting membranes or in the cytosol. A
previous study suggested that HPV L2 bound to the lipid bilayer of
endosomal compartments and destabilized the membrane, according
to a decrease of the internal pH (Kämper et al., 2006); this eventually
led to the viral genome entering the nucleus. Anti-P56/75 binds to the
L2 region displayed on the surface of HPV pseudovirus (Kondo et al.,
2007) and may thereby block an L2 function necessary for binding to
and destabilizing the limiting membrane.
In summary, 16PV alone and antibody-bound 16PV showed similar
attachment to the surface of HeLa cells. Almost all of the cell-attached
16PV and approximately 80% of the cell-attached antibody-bound
16PV entered cells by endocytosis after incubation at 37 °C.
Approximately 20% of the cell-attached antibody-bound particles
remained on the surface, where they formed aggregates. A portion of
the 16PV particles exited the vesicles and transported the packaged
DNA to the nucleus. In contrast, all of the antibody-bound 16PV
particles remained in vesicles, to be degraded after the fusion of the
vesicles with lysosomes. It is likely that an L2 function essential for
egress from vesicles is abrogated by the binding of anti-P56/75
antibody. This study suggests that anti-P56/75 inhibits HPV infection
partly by blocking viral entry and primarily by blocking the transport
of the viral genome to the nucleus.
Materials and methods
Cells
The 293FT cell line expressing a high level of SV40 T-antigen was
purchased from Life Technologies Corp. (Carlsbad, CA, USA). The
293FT and HeLa cells were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM) (Life Technologies Corp.) supplemented with 10%
fetal bovine serum, 100 units/ml penicillin G potassium (Meiji Seika
Ltd., Tokyo, Japan), and 60 μg/ml kanamycin sulfate (Wako Pure
Chemical Industries Ltd., Tokyo, Japan) at 37 °C in 5% CO2.
Production of 16PV
The 16PV consisted of a HPV16 capsid containing a reporter
plasmid encoding enhanced green ﬂuorescence protein (pEF1a-
EGFP) and was produced as described previously (Ishii et al., 2007;
Kondo et al., 2007). To label the 16PV-packaged DNA with 5-ethynil-
2′-deoxyuridine (EdU) (Life Technologies Corp.), 293FT cells (1×107)
were incubated for 16 h in a 10-cm culture dish; transfected with a
mixture of p16L1h (13.5 μg), p16L2h (3 μg), and pYSEAP (13.5 μg)
(Kondo et al., 2007) by using Fugene HD (Roche Diagnostics GmbH,
Mannheim, Germany); incubated for 6 h at 37 °C; and supplemented
with 100 μM EdU. After 60 h, the cells were harvested using a cell
scraper, suspended in 500 μl of lysis buffer [PBS containing 1 mM
CaCl2, 10 mMMgCl2, 0.35% Brij58 (Sigma-Aldrich, St. Louis, MO, USA),
0.1% benzonase (Sigma-Aldrich), 0.1% plasmid-safe ATP-dependent
DNase (Epicentre Corp., Madison, WI, USA), and 1 mM ATP], and
incubated for 30 h at 37 °C with slow rotation, in the dark. The lysate
was cooled on ice for 5 min, mixed with 5 M NaCl to a ﬁnal NaCl
concentration of 1 M, kept on ice for 10 min, and then centrifuged at
5000×g for 10 min at 4 °C. The supernatant was placed on an
Optiprep (Axis-Shield PoC AS, Oslo, Norway) gradient (from top to
bottom, 27%, 33%, and 39% in PBS containing 1 mM CaCl2, 10 mM
MgCl2, and 0.85 M NaCl) and centrifuged at 50,000 rpm for 3.5 h at
16 °C in an SW55Ti rotor (Beckman Coulter Inc., Fullerton, CA, USA).
Fractions (400 μl each) were obtained by puncturing the bottom of
the tube. Aliquots (5 μl per fraction) were analyzed by SDS-PAGE. The
fraction in which L1 was most abundant was used as the 16PV stock.
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The 16PV (0.25 μg or 2.5 μg of L1) was mixed with normal rabbit
serum (Life Technologies Corp.) or rabbit anti-P56/75 serum (Kondo
et al., 2007), at serial dilutions from 1:20 to 1:800, in 500 μl of growth
medium and incubated at 37 °C for 30 min. Each mixture was added
to HeLa cells (1.5×105) in 24-well plates. After incubation for 2 days,
the cells were examined under a BZ-8000 ﬂuorescence microscope
(Keyence, Osaka, Japan) and harvested using trypsin. EGFP-positive
cells were counted by ﬂow cytometry (FACSCalibur; Becton Dickinson
and Co., San Jose, CA, USA).
Western blot assay
The 16PV (2.5 μg of L1) was mixed with normal rabbit serum or
rabbit anti-P56/75 serum (1:20 dilution) in 500 μl of growth medium
and incubated at 37 °C for 30 min. Each mixture was added to HeLa
cells (1.5×105) in 24-well plates. The cells were incubated for 1 h at
4 °C, washed with PBS, harvested in PBS containing 2.5 mM EDTA, and
lysed. The lysate proteins were separated by SDS-PAGE and
transferred to a polyvinylidene diﬂuoride membrane. The L1 protein
was detected by immunoblottingwithmousemonoclonal anti-HPV16
L1 antibody (BD Biosciences Pharmingen, San Diego, CA, USA),
followed by anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Immunoreactive bands were visualized using an
ECL Plus Western blot detection system (GE Healthcare UK Ltd., Little
Chalfont, Buckinghamshire, England) and Typhoon 9410 (GE Health-
care UK Ltd.).
Internalization assay
The 16PV (2.5 μg of L1) was mixed with normal rabbit serum or
rabbit anti-P56/75 serum (1:20 dilution) in 500 μl of growth medium
and incubated at 37 °C for 30 min. Each mixture was added to HeLa
cells (1.5×105) in 24-well plates. After incubation for 1 h at 4 °C, the
cells were washed with PBS, cultured at 37 °C for 0, 2, 4, 8, and 22 h,
and harvested with PBS containing trypsin (trypsin+) or containing
2.5 mM EDTA (trypsin−). The cells were lysed and electrophoresed in
a SDS-polyacrylamide gel. The separated proteins were transferred to
a polyvinylidene diﬂuoride membrane, and a Western blot was
performed as described above.
Immunoﬂuorescence assay
The 16PV (2.5 μg of L1) containing EdU-labeled DNA was mixed
with normal rabbit serum or rabbit anti-P56/75 serum (1:20 dilution)
in 500 μl of growth medium and incubated at 37 °C for 30 min. The
mixture was added to HeLa cells (1.5×105) in the wells of four-
chamber glass slides (BD Biosciences Falcon, Bedford, MA, USA),
followed by incubation for 1 h at 4 °C. The cells were washed with
growth medium, incubated in growth medium for 0, 2, 4, 8, and 22 h
at 37 °C, washed with PBS, and ﬁxed with methanol for 30 min at
−20 °C. After washing twice with 3% BSA in PBS for 5 min, the cells
were incubated with Click-it Reaction Cocktail containing Alexa Fluor
488 (Click-it™ EdU imaging kit; Life Technologies Corp.) for 30 min at
room temperature (RT) in the dark and again washed twice with 3%
BSA in PBS for 5 min. Next, the cells were incubated with mouse anti-
HPV16 L1 polyclonal antiserum, which had been produced previously
by immunizing mice with HPV16 L1 VLP (Ishii et al., 2003), in PBS
containing 3% BSA for 1 h at RT and washed with PBS containing 0.2%
Tween-20. The cells were then incubated with Alexa Fluor 555-
conjugated goat anti-mouse IgG (H+L) (Life Technologies Corp.) in
PBS containing 3% BSA, washed with PBS containing 0.2% Tween-20,
and mounted with ProLong Gold anti-fade reagent with DAPI (Life
Technologies Corp.). Fluorescence was examined using a Fluoview
FV1000 confocal microscope (Olympus, Tokyo, Japan).Electron microscopy
The 16PV (10 μg of L1) was mixed with normal rabbit serum or
rabbit anti-P56/75 serum (1:10 dilution) in 1 ml of growth medium
and incubated at 37 °C for 30 min. Each mixture was added to HeLa
cells (6×105) in 35-mm culture plates. After incubation at 37 °C for
1 h, 1 ml of growth mediumwas added to the cells, and the cells were
incubated at 37 °C for another 3 h (4 h total). After incubation, the
cells were preﬁxed in 2.5% glutaraldehyde/0.1 M phosphate buffer at
RT for 2 h, washedwith phosphate buffer for 30 min, and post-ﬁxed in
1% osmium tetroxide for 1 h. Following dehydration in a graded series
of ethanol solutions, the cells were embedded in a mixture of Epoxy
812, DDSA, MNA, and DMP-30 at 60 °C for 2 days. Ultra-thin sections
(70 nm) were cut parallel to the substrate, stained with 4% uranyl
acetate, and examined under a Hitachi H-7650 transmission electron
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